“We develop strategies that empower our clients to drive innovation and bring new treatments from promises to patients.”

“At Catenion, I can put my scientific background in cell therapy and regenerative medicine to practical use and help bring innovative therapies to the market.”

Dr. Pascal Joly Principal

“Increasingly, bioconvergent therapeutics and hybrid products and services promise cures; with current pharmaco-economic pricing rationales, these will be cost-effective but they will

bankrupt the system.”

Christian Elze Senior Partner

“Helping clients around the globe to unleash the power of immune system in the fight against a plethora of diseases is a very rewarding career path for a trained immunologist.”

Dr. Jelena Nedjic Principal

“Is biopharma ready to embrace the new biology?”

Dr. Markus Thunecke Senior Partner

“Translating new technologies into viable business ideas”

Arno Heuermann COO, Partner/ Managing Director

“Change-Management is a team effort – let’s get started.”

Dr. Matthias Krings Senior Partner

“Catenion provides an exciting workplace where science meets business. We aim to help our clients to reach patients sooner and better.”

Spotlight

2020 Global Biopharma R&D Productivity And Growth Ranking

THE DECREASE IN OVERALL R&D PRODUCTIVITY continues – a trend that started in 2018. It would be too easy to attribute this fall in R&D productivity to COVID-19 alone.
Download this article

Predicting Success of Clinical Trials

In spite of huge progress in understanding disease biology and technological advances in patient selection and clinical study design, the failure rates of clinical trials are still very high. According to Hay et al. [1] the probability of drugs in phase III to get approved across different indications was only 50%. This is noteworthy in […]
more

Meet Us

May 6th, 2021

Max Planck Career Evolution: From Science2industry talk

more
Nov 4th, 2021

Berlin Buch Campus: Postdoc Day MDC & FMP

more